Simcere (2096) Enters Exclusive Licensing with Vigonvita (2630.HK) for Deuterated Remdesivir Hydrobromide

Bulletin Express

Dec 03, 2025

Simcere Pharmaceutical Group Limited (Simcere, Stock code: 2096) announced the signing of a license agreement with Vigonvita Life Science Co., Ltd. (Vigonvita, 2630.HK) on December 3, 2025, involving new indications for Deuterated Remdesivir Hydrobromide in the Greater China region. The treatment targets respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection.

Deuterated Remdesivir Hydrobromide is an oral nucleoside antiviral candidate that inhibits viral RNA-dependent RNA polymerase (RdRp). A Phase II clinical trial in China examining the therapy in infants and young children aged 1–24 months for RSV infection has concluded, demonstrating favorable antiviral efficacy and a good safety profile. As a result, the dry suspension formulation received Breakthrough Therapy designation from the Center for Drug Evaluation of the National Medical Products Administration. In addition, the tablet formulation previously garnered full approval in China for the treatment of mild-to-moderate COVID-19 in adults.

Vigonvita focuses on developing novel drugs in neuropsychiatry, reproductive health, and viral infections. Simcere, an R&D-driven pharmaceutical group, aims to strengthen its anti-infection product portfolio through this new collaboration, supported by its in-house research and collaborations with innovative partners.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159415767"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159415767\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159415767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159415767","market":"hk","top_or_hot":-1,"title":"Simcere (2096) Enters Exclusive Licensing with Vigonvita (2630.HK) for Deuterated Remdesivir Hydrobromide","media":"Bulletin Express","content":"<p>Simcere Pharmaceutical Group Limited (Simcere, Stock code: 2096) announced the signing of a license agreement with Vigonvita Life Science Co., Ltd. (Vigonvita, 2630.HK) on December 3, 2025, involving new indications for Deuterated Remdesivir Hydrobromide in the Greater China region. The treatment targets respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection.</p>\n<p>Deuterated Remdesivir Hydrobromide is an oral nucleoside antiviral candidate that inhibits viral RNA-dependent RNA polymerase (RdRp). A Phase II clinical trial in China examining the therapy in infants and young children aged 1–24 months for RSV infection has concluded, demonstrating favorable antiviral efficacy and a good safety profile. As a result, the dry suspension formulation received Breakthrough Therapy designation from the Center for Drug Evaluation of the National Medical Products Administration. In addition, the tablet formulation previously garnered full approval in China for the treatment of mild-to-moderate COVID-19 in adults.</p>\n<p>Vigonvita focuses on developing novel drugs in neuropsychiatry, reproductive health, and viral infections. Simcere, an R&D-driven pharmaceutical group, aims to strengthen its anti-infection product portfolio through this new collaboration, supported by its in-house research and collaborations with innovative partners.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere (2096) Enters Exclusive Licensing with Vigonvita (2630.HK) for Deuterated Remdesivir Hydrobromide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere (2096) Enters Exclusive Licensing with Vigonvita (2630.HK) for Deuterated Remdesivir Hydrobromide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-03 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Simcere Pharmaceutical Group Limited (Simcere, Stock code: 2096) announced the signing of a license agreement with Vigonvita Life Science Co., Ltd. (Vigonvita, 2630.HK) on December 3, 2025, involving new indications for Deuterated Remdesivir Hydrobromide in the Greater China region. The treatment targets respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection.</p>\n<p>Deuterated Remdesivir Hydrobromide is an oral nucleoside antiviral candidate that inhibits viral RNA-dependent RNA polymerase (RdRp). A Phase II clinical trial in China examining the therapy in infants and young children aged 1–24 months for RSV infection has concluded, demonstrating favorable antiviral efficacy and a good safety profile. As a result, the dry suspension formulation received Breakthrough Therapy designation from the Center for Drug Evaluation of the National Medical Products Administration. In addition, the tablet formulation previously garnered full approval in China for the treatment of mild-to-moderate COVID-19 in adults.</p>\n<p>Vigonvita focuses on developing novel drugs in neuropsychiatry, reproductive health, and viral infections. Simcere, an R&D-driven pharmaceutical group, aims to strengthen its anti-infection product portfolio through this new collaboration, supported by its in-house research and collaborations with innovative partners.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1159415767","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159415767","pubTimestamp":1764751657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Simcere Pharmaceutical Group Limited (Simcere, Stock code: 2096) announced the signing of a license agreement with Vigonvita Life Science Co., Ltd. (Vigonvita, 2630.HK) on December 3, 2025, involving...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业"},"translate_title":"先声药业(2096)与Vigonvita(2630.HK)签订氘代瑞德西韦氢溴酸盐独家授权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Simcere Pharmaceutical Group Limited (Simcere, Stock code: 2096) announced the signing of a license agreement with Vigonvita Life Science Co., Ltd. (Vigonvita, 2630.HK) on December 3, 2025, involving new indications for Deuterated Remdesivir Hydrobromide in the Greater China region. The treatment targets respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection.\nDeuterated Remdesivir Hydrobromide is an oral nucleoside antiviral candidate that inhibits viral RNA-dependent RNA polymerase (RdRp). A Phase II clinical trial in China examining the therapy in infants and young children aged 1–24 months for RSV infection has concluded, demonstrating favorable antiviral efficacy and a good safety profile. As a result, the dry suspension formulation received Breakthrough Therapy designation from the Center for Drug Evaluation of the National Medical Products Administration. In addition, the tablet formulation previously garnered full approval in China for the treatment of mild-to-moderate COVID-19 in adults.\nVigonvita focuses on developing novel drugs in neuropsychiatry, reproductive health, and viral infections. Simcere, an R&D-driven pharmaceutical group, aims to strengthen its anti-infection product portfolio through this new collaboration, supported by its in-house research and collaborations with innovative partners.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}